NTRA Stock Overview
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Natera, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$87.28 |
52 Week High | US$98.82 |
52 Week Low | US$36.90 |
Beta | 1.39 |
1 Month Change | -4.36% |
3 Month Change | 30.99% |
1 Year Change | 60.91% |
3 Year Change | -18.38% |
5 Year Change | 362.78% |
Change since IPO | 283.82% |
Recent News & Updates
Recent updates
Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?
Mar 30Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
Mar 22Is Natera (NASDAQ:NTRA) A Risky Investment?
Mar 03Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)
Dec 11Is Natera (NASDAQ:NTRA) A Risky Investment?
Nov 10Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate
Aug 07Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
May 16Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement
Apr 18Natera: Cracks In The Bearish Trade
Oct 10Natera gains after publication of data on transplant rejection assessment test
Oct 04Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?
Sep 13Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer
Jul 18Shareholder Returns
NTRA | US Biotechs | US Market | |
---|---|---|---|
7D | -9.8% | -4.7% | -3.7% |
1Y | 60.9% | -2.7% | 20.2% |
Return vs Industry: NTRA exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: NTRA exceeded the US Market which returned 20.5% over the past year.
Price Volatility
NTRA volatility | |
---|---|
NTRA Average Weekly Movement | 5.6% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTRA's share price has been volatile over the past 3 months.
Volatility Over Time: NTRA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 3,288 | Steve Chapman | www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
Natera, Inc. Fundamentals Summary
NTRA fundamental statistics | |
---|---|
Market cap | US$10.54b |
Earnings (TTM) | -US$434.80m |
Revenue (TTM) | US$1.08b |
9.7x
P/S Ratio-24.2x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NTRA income statement (TTM) | |
---|---|
Revenue | US$1.08b |
Cost of Revenue | US$589.83m |
Gross Profit | US$492.74m |
Other Expenses | US$927.54m |
Earnings | -US$434.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.60 |
Gross Margin | 45.52% |
Net Profit Margin | -40.16% |
Debt/Equity Ratio | 47.5% |
How did NTRA perform over the long term?
See historical performance and comparison